FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096698984> ?p ?o ?g. }

• W2096698984 endingPage "233S" @default.
• W2096698984 startingPage "204S" @default.
• W2096698984 abstract "This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring of anticoagulation intensity, the clinical applications of VKA therapy, and the optimal therapeutic range of VKAs, and provides specific management recommendations. Grade 1 recommendations are strong, and indicate that the benefits do, or do not, outweigh the risks, burdens, and costs. Grade 2 suggests that individual patient's values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S–187S). Among the key recommendations in this article are the following: for dosing of VKAs, we suggest the initiation of oral anticoagulation therapy with doses between 5 and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 2B). In the elderly and in other patient subgroups with an elevated bleeding risk, we suggest a starting dose at ≤ 5 mg (Grade 2C). We recommend basing subsequent doses after the initial two or three doses on the results of INR monitoring (Grade 1C). The article also includes several specific recommendations for the management of patients with INRs above the therapeutic range and for patients requiring invasive procedures. For example, in patients with mild to moderately elevated INRs without major bleeding, we suggest that when vitamin K is to be given it be administered orally rather than subcutaneously (Grade 1A). For the management of patients with a low risk of thromboembolism, we suggest stopping warfarin therapy approximately 4 days before they undergo surgery (Grade 2C). For patients with a high risk of thromboembolism, we suggest stopping warfarin therapy approximately 4 days before surgery, to allow the INR to return to normal, and beginning therapy with full-dose unfractionated heparin or full-dose low-molecular-weight heparin as the INR falls (Grade 2C). In patients undergoing dental procedures, we suggest the use of tranexamic acid mouthwash (Grade 2B) or epsilon amino caproic acid mouthwash without interrupting anticoagulant therapy (Grade 2B) if there is a concern for local bleeding. For most patients who have a lupus inhibitor, we suggest a therapeutic target INR of 2.5 (range, 2.0 to 3.0) [Grade 2B]. In patients with recurrent thromboembolic events with a therapeutic INR or other additional risk factors, we suggest a target INR of 3.0 (range, 2.5 to 3.5) [Grade 2C]. As models of anticoagulation monitoring and management, we recommend that clinicians incorporate patient education, systematic INR testing, tracking, and follow-up, and good communication with patients concerning results and dosing decisions (Grade 1C+). This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring of anticoagulation intensity, the clinical applications of VKA therapy, and the optimal therapeutic range of VKAs, and provides specific management recommendations. Grade 1 recommendations are strong, and indicate that the benefits do, or do not, outweigh the risks, burdens, and costs. Grade 2 suggests that individual patient's values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S–187S). Among the key recommendations in this article are the following: for dosing of VKAs, we suggest the initiation of oral anticoagulation therapy with doses between 5 and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 2B). In the elderly and in other patient subgroups with an elevated bleeding risk, we suggest a starting dose at ≤ 5 mg (Grade 2C). We recommend basing subsequent doses after the initial two or three doses on the results of INR monitoring (Grade 1C). The article also includes several specific recommendations for the management of patients with INRs above the therapeutic range and for patients requiring invasive procedures. For example, in patients with mild to moderately elevated INRs without major bleeding, we suggest that when vitamin K is to be given it be administered orally rather than subcutaneously (Grade 1A). For the management of patients with a low risk of thromboembolism, we suggest stopping warfarin therapy approximately 4 days before they undergo surgery (Grade 2C). For patients with a high risk of thromboembolism, we suggest stopping warfarin therapy approximately 4 days before surgery, to allow the INR to return to normal, and beginning therapy with full-dose unfractionated heparin or full-dose low-molecular-weight heparin as the INR falls (Grade 2C). In patients undergoing dental procedures, we suggest the use of tranexamic acid mouthwash (Grade 2B) or epsilon amino caproic acid mouthwash without interrupting anticoagulant therapy (Grade 2B) if there is a concern for local bleeding. For most patients who have a lupus inhibitor, we suggest a therapeutic target INR of 2.5 (range, 2.0 to 3.0) [Grade 2B]. In patients with recurrent thromboembolic events with a therapeutic INR or other additional risk factors, we suggest a target INR of 3.0 (range, 2.5 to 3.5) [Grade 2C]. As models of anticoagulation monitoring and management, we recommend that clinicians incorporate patient education, systematic INR testing, tracking, and follow-up, and good communication with patients concerning results and dosing decisions (Grade 1C+)." @default.
• W2096698984 created "2016-06-24" @default.
• W2096698984 creator A5000914852 @default.
• W2096698984 creator A5012584739 @default.
• W2096698984 creator A5014841232 @default.
• W2096698984 creator A5053834023 @default.
• W2096698984 creator A5057316883 @default.
• W2096698984 creator A5080799947 @default.
• W2096698984 date "2004-09-01" @default.
• W2096698984 modified "2023-10-14" @default.
• W2096698984 title "The Pharmacology and Management of the Vitamin K Antagonists" @default.
• W2096698984 cites W107120791 @default.
• W2096698984 cites W108198928 @default.
• W2096698984 cites W118141064 @default.
• W2096698984 cites W1458746074 @default.
• W2096698984 cites W1497998463 @default.
• W2096698984 cites W1501820105 @default.
• W2096698984 cites W1511722589 @default.
• W2096698984 cites W1519815496 @default.
• W2096698984 cites W1522694313 @default.
• W2096698984 cites W1527880353 @default.
• W2096698984 cites W1544495290 @default.
• W2096698984 cites W1555429860 @default.
• W2096698984 cites W1565329824 @default.
• W2096698984 cites W1572883374 @default.
• W2096698984 cites W1576256885 @default.
• W2096698984 cites W1582107629 @default.
• W2096698984 cites W1594886297 @default.
• W2096698984 cites W1603870906 @default.
• W2096698984 cites W1603919509 @default.
• W2096698984 cites W1661585479 @default.
• W2096698984 cites W1782728159 @default.
• W2096698984 cites W1785968800 @default.
• W2096698984 cites W1851325607 @default.
• W2096698984 cites W188784659 @default.
• W2096698984 cites W193607663 @default.
• W2096698984 cites W1939117920 @default.
• W2096698984 cites W1965072027 @default.
• W2096698984 cites W1966282846 @default.
• W2096698984 cites W1966620398 @default.
• W2096698984 cites W1967550469 @default.
• W2096698984 cites W1967698600 @default.
• W2096698984 cites W1971522207 @default.
• W2096698984 cites W1972452854 @default.
• W2096698984 cites W1974119632 @default.
• W2096698984 cites W1974943162 @default.
• W2096698984 cites W1975137698 @default.
• W2096698984 cites W1975500359 @default.
• W2096698984 cites W1978193003 @default.
• W2096698984 cites W1978313703 @default.
• W2096698984 cites W1979288586 @default.
• W2096698984 cites W1979363567 @default.
• W2096698984 cites W1980784832 @default.
• W2096698984 cites W1981746689 @default.
• W2096698984 cites W1983735691 @default.
• W2096698984 cites W1987034302 @default.
• W2096698984 cites W1987381409 @default.
• W2096698984 cites W1989653273 @default.
• W2096698984 cites W1991549653 @default.
• W2096698984 cites W1992389349 @default.
• W2096698984 cites W1993543402 @default.
• W2096698984 cites W1993615487 @default.
• W2096698984 cites W1994495551 @default.
• W2096698984 cites W1994775726 @default.
• W2096698984 cites W1994894525 @default.
• W2096698984 cites W1996156310 @default.
• W2096698984 cites W1996667418 @default.
• W2096698984 cites W1996795473 @default.
• W2096698984 cites W1997667641 @default.
• W2096698984 cites W1997682915 @default.
• W2096698984 cites W1998754873 @default.
• W2096698984 cites W2001272791 @default.
• W2096698984 cites W2001411232 @default.
• W2096698984 cites W2001473873 @default.
• W2096698984 cites W2001523104 @default.
• W2096698984 cites W2001753560 @default.
• W2096698984 cites W2002261292 @default.
• W2096698984 cites W2002278275 @default.
• W2096698984 cites W2002576379 @default.
• W2096698984 cites W2004068195 @default.
• W2096698984 cites W2004337162 @default.
• W2096698984 cites W2004423916 @default.
• W2096698984 cites W2005278360 @default.
• W2096698984 cites W2005734831 @default.
• W2096698984 cites W2006271928 @default.
• W2096698984 cites W2006587134 @default.
• W2096698984 cites W2007303097 @default.
• W2096698984 cites W2008030496 @default.
• W2096698984 cites W2008617085 @default.
• W2096698984 cites W2008635765 @default.
• W2096698984 cites W2009013630 @default.
• W2096698984 cites W2009340266 @default.
• W2096698984 cites W2012923240 @default.
• W2096698984 cites W2013749044 @default.
• W2096698984 cites W2014872803 @default.
• W2096698984 cites W2016729646 @default.
• W2096698984 cites W2017836681 @default.
• W2096698984 cites W2024597661 @default.

• next